-
Other countries outside the US are also expressing and formulating their clinical trial business in India. Of late there have been a multitude of these reportings, it doesn’t appear India will be lacking in the R and D trial business any time soon. BD The operation will be run by the...
-
Nothing new here in what has been posted, but this time the predictions are coming from within Ernst and Young from India. BD The Indian clinical trials market is predicted to continue its growth despite the current financial climate, according to a partner at Ernst & Young India’s Healthsciences...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-25-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, healthcare, Pharma, clinical trials, R and D, India, Economics, Outsourcing, Employment, Clinic
-
The post is a summary of how things look today and under related reading I have included some past posts that may offer a few more details on how the shift it taking place today. Things are also happening and humming as well in China and you can search and find some recent relative posts here as...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-20-2008
Filed under:
Filed under: Pharma/FDA News, My Commentaries, healthcare, Pharma, clinical trials, R and D, India, Economics, Mayo Clinic, Outsourcing, Employment, China pharma
-
The trial is for women who have the HER2 gene and have already received treatments, details listed below. BD The Barbara Ann Karmanos Institute is looking for women with HER2 positive metastatic breast cancer to participate in a clinical trial. The Phase II trial at Karmanos is part of an...
-
This also means some folks will be losing jobs as well. The unit has been in place since 1991 and has provided information on over 1,000 trials. This is just one more sign of how the face of the pharmaceutical business is changing. It is about one fifth the cost to run trials in countries...
-
Great effort on the members of Congress to “ask”, but the end result is what counts. R and D with major pharmaceutical companies is presently in the business of moving overseas to India and China, as well as some clinical trials, so the impact of the request from the members of Congress may or...
-
The National Cancer Institute has made clinical trial participation a top national priority and yet participant levels are still not perhaps where they could be. Yes, this is a big decision for any patient/physician to make as far as whether or not to enroll, but many trials are offering lifesaving...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-02-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, My Commentaries, Investors, health insurance, Pharma, Cancer, clinical trials, HMO, Pharmaceuticals, R and D, Drug Development, Cancer Institute
-
This is bringing everything full circle with not only being able to research trials, but results will now be listed as well. As you can see it literally took an “act of Congress” to get the ball rolling. In time as reporting begins the web site will also be able to offer the results as well...
-
Other Pharma businesses have done or will be doing the same, much of R and D is moving other areas where the cost is 1/5 of that here in the US, so 5 times the number of projects ongoing for the same amount of money, which also means in the same terms there can be 4 failures of drugs in the same cost...
-
Not just India, but other countries as well. I have posted many articles on the blog referencing outsourcing over the last year or so and all of Big Pharma has interests in foreign countries including the strong possibility of phase 1 clinical trials. The one comment I have to make here...
-
This is probably a good move to speed this process up since many pharmaceutical companies have and are looking at moving more trials to India. More information can be read here about the changing face of Pharma in reference to research and development. One more area to think about too is the use...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-19-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Cancer, clinical trials, Congress, DNA Testing, National Cancer Institute, Justice Department
-
With clinical trials becoming a bit more complicated, and with new processes of running genomic related reports during the time frame, it is getting to be a bit of a complicated issue, thus now there are services that will help find the appropriate candidates for the trials. No longer is it perhaps...
-
I am guessing this stands to be topic for all in the Pharma business to keep an eye on. There are those in the Indian government too with reservations. The whole idea here is to save money over what the same might cost in the US, as reported earlier, 1/5 is the cost for R and D, thus this...
-
With all the focus on cancer of late, which is of course very important, it's nice to see some other research and good clinical results for other chronic conditions, such as Gout. I have watch my mother, who is 84 years old, and who is also a diabetic who has gout, for years, trying to balance...
-
Right now according to the Wall Street Journal, patients who have enjoyed an open relationship are worried that this could all change under management from Roche. Is bigger always better? Recently in the news Genentech is not happy with the offer and may hold out for more. Anyone that...